Clinical Trials Sponsored by Bioniz Therapeutics

Total 6550 results

Bioniz Therapeutics

Completed

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

LGL Leukemia | CTCL

United States
Bioniz Therapeutics
Celerion

Completed

A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects

Safety and Tolerability in Healthy Subjects

United States
Bioniz Therapeutics
Celerion

Completed

A First-in-Human Study of BNZ132-1-40

Healthy

United States
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Idiopathic Parkinson Disease

United States, Canada, United Kingdom
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Abuse Potential

Canada
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome

United States, Brazil, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, South Africa, Spain, United Kingdom
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Cardiovascular Disease | Elevated Lipoprotein(a)

United States, Canada, Denmark, Germany, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Elevated Lipoprotein(a)

Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Withdrawn

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada, France, Germany, United Kingdom, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Familial Partial Lipodystrophy

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Diabetes Mellitus, Type 2 | NAFLD | Hypertriglyceridemia | Fatty Liver, Nonalcoholic

United States, Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Hypertriglyceridemia | Familial Hypercholesterolemia

Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE)

Familial Chylomicronemia Syndrome

United States, Israel, Spain, Italy, United Kingdom, Netherlands, Canada, Hungary, Sweden, France, Norway, Portugal, Slovakia
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Cardiovascular Diseases | Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Abnormalities, Cardiovascular

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Elevated Triglycerides (TG)

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditions

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Hypercholesterolemia | Coronary Heart Disease

South Africa, Germany, United States, United Kingdom, Canada, Czech Republic
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Healthy Volunteer

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Hypercholesterolemia | Coronary Heart Disease

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers

Healthy Volunteer

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects (ASSIST)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic Disorder

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (RADICHOL II)

Coronary Artery Disease | Heterozygous Familial Hypercholesterolemia

United States, Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia (RADICHOL 1)

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

Healthy

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Bionic Sight LLC

Recruiting

BS01 in Patients With Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Bionov

Unknown

Evaluation of SODB® (Superoxide Dismutase by Bionov®) in the Physical Condition Improvement in Healthy Subjects (MELORUN560)

Healthy Volunteers
Advanced Bionics AG
Advanced Bionics

Completed

Evaluation of Different Phone Solutions in CI and Hearing Aid Users and Bimodal Recipients (PhoneCIHA)

Hearing Loss, Binaural | Hearing Loss, Monaural

Switzerland
Bionov

Unknown

Evaluation of SODB® in Metabolic Adaptations in Overweight Women (SORESCAL)

Overweight
Cionic, Inc.

Recruiting

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting

United States
Bionov
BioFortis

Completed

Evaluation of the Effects of a Food Supplementation on the Improvement of Cognitive Functions in Healthy Seniors (BioMind)

Healthy Subjects

France
BioVie Inc.

Terminated

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

Decompensated Cirrhosis | Ascites

United States
Abionic SA

Completed

Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2

COVID-19 | COVID-19 Pandemic

Italy
Ekso Bionics

Completed

Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

Debility Due to Disease

United States
Advanced Bionics

Terminated

Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Loss | Hearing Disorders | Partial Deafness

United States
Advanced Bionics

Completed

Clinical Evaluation of a Cochlear Implant Sound Processor

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Loss | Hearing Disorders

United States

Clinical Trials Sponsored by Bioniz Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations